Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFF269 in Essential Hypertension
NCT01373086Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LFF269 in essential hypertension (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean 24-hour systolic blood pressure by ambulatory blood pressure monitoring at 4 weeks. Started May 2011; status: terminated.
02
Drugs
LFF269
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT01373086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373086.